Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LY900014 Formulations in Healthy Subjects
NCT03616977Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under the Concentration Curve From Time Zero to 10 Hours. Started Aug 2018; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03616977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616977.